These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32088343)

  • 1. S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer.
    Zhang YH; Luo DD; Wan SB; Qu XJ
    Pharmacol Res; 2020 May; 155():104717. PubMed ID: 32088343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel 5-fluorouracil sensitizers for colorectal cancer therapy: Design and synthesis of S1P receptor 2 (S1PR2) antagonists.
    Luo D; Guo Z; Zhao X; Wu L; Liu X; Zhang Y; Zhang Y; Deng Z; Qu X; Cui S; Wan S
    Eur J Med Chem; 2022 Jan; 227():113923. PubMed ID: 34688013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and evaluation of JTE-013 derivatives as novel potent S1PR2 antagonists for recovering the sensitivity of colorectal cancer to 5-fluorouracil.
    Guo Z; Zhang S; Liu X; Zhao G; Zhang Y; Luo D; Zhao X; Xu X; Qu X; Li L; Wan S; Cui S
    Bioorg Chem; 2023 Feb; 131():106318. PubMed ID: 36527992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased S1P induces S1PR2 internalization to blunt the sensitivity of colorectal cancer to 5-fluorouracil via promoting intracellular uracil generation.
    Zhang YH; Cui SX; Wan SB; Wu SH; Qu XJ
    Acta Pharmacol Sin; 2021 Mar; 42(3):460-469. PubMed ID: 32647340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
    Luo D; Zhang Y; Yang S; Tian X; Lv Y; Guo Z; Liu X; Han G; Liu S; Wang W; Cui S; Qu X; Wan S
    Eur J Med Chem; 2021 Dec; 225():113775. PubMed ID: 34411894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational Design, Synthesis, and Biological Evaluation of Novel S1PR2 Antagonists for Reversing 5-FU-Resistance in Colorectal Cancer.
    Luo D; Liu X; Jiang L; Guo Z; Lv Y; Tian X; Wang X; Cui S; Wan S; Qu X; Xu X; Li X
    J Med Chem; 2022 Nov; 65(21):14553-14577. PubMed ID: 36269639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
    Li LH; Dong H; Zhao F; Tang J; Chen X; Ding J; Men HT; Luo WX; Du Y; Ge J; Tan BX; Cao D; Liu JY
    Eur J Cancer; 2013 May; 49(7):1752-60. PubMed ID: 23313143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression.
    Zhang YH; Shi WN; Wu SH; Miao RR; Sun SY; Luo DD; Wan SB; Guo ZK; Wang WY; Yu XF; Cui SX; Qu XJ
    Oncogene; 2020 Jul; 39(29):5214-5227. PubMed ID: 32546724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
    Réti A; Pap E; Adleff V; Jeney A; Kralovánszky J; Budai B
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):219-27. PubMed ID: 19830428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
    Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
    Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
    Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [5-fluorouracil and dihydropyrimidine dehydrogenase].
    Kubota T
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
    Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer.
    Araki Y; Isomoto H; Shirouzu K
    Kurume Med J; 2001; 48(2):93-8. PubMed ID: 11501504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of two fluorouracil administration regimens for colorectal cancer.
    Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
    Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine.
    Ikeguchi M; Hirooka Y; Makino M; Kaibara N
    Oncol Rep; 2001; 8(3):621-5. PubMed ID: 11295091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.
    Isshi K; Sakuyama T; Gen T; Nakamura Y; Kuroda T; Katuyama T; Maekawa Y
    Int J Clin Oncol; 2002 Dec; 7(6):335-42. PubMed ID: 12494248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.